Image

The Impact of Oxidative Stress on Erythrocyte Biology

The Impact of Oxidative Stress on Erythrocyte Biology

Non Recruiting
18-60 years
All
Phase 2

Powered by AI

Overview

This study will address if red blood cells transfused to a sickle cell patient from a donor with a glucose-6-phosphate-dehydrogenase (G6PD) enzyme deficiency have a different lifespan as measured by the percentage of red blood cells that survive post-transfusion compared to red blood cells transfused to a sickle cell patient from a donor without a G6PD enzyme deficiency.

Description

This prospective, phase II, crossover, single-blind, randomized transfusion order study will address if red blood cells from donors with a G6PD enzyme deficiency have a different lifespan once transfused into a patient with sickle cell disease than red blood cells from an otherwise normal donor. Results of this critical study will guide future research and donor testing policies to ensure that patients receive the most appropriate units of blood for their condition. Each patient randomized to the study will receive 2 blood transfusions, one from a G6PD deficient donor and one from an otherwise normal donor. Half the patients (8) will receive G6PD deficient blood first while the other half (8) will receive non-G6PD deficient blood first. Patients will have a wash-out period of at least 4 months before receiving the opposite type of blood transfusion. The blood transfusion order will be randomized. There is currently no standard of testing in place to screen blood donations for G6PD enzyme deficiency. It is believed that up to 10% of the antigen-matched donors for patients with sickle cell disease are G6PD deficient, and the lifespan is unknown in the sickle cell population.

Eligibility

Inclusion Criteria:

  • Age 18-60 years
  • Has diagnosis of sickle cell disease
  • Steady state (no pain or baseline pain and ≥1 month from any hospital admission)
  • Receiving chronic transfusions (i.e., regular transfusion every 4-8 weeks).

Exclusion Criteria:

  • History of transfusion reactions not adequately managed by antihistamines
  • Does not have crossmatch compatible red cells
  • Known G6PD deficiency
  • Hepato- or splenomegaly
  • Participation in another therapeutic trial
  • Pregnant or nursing
  • HIV positive
  • At investigator discretion for uncontrolled inter-current illness or social situation limiting compliance with study requirements.
  • Inability to speak and/or read English

Study details
    Sickle Cell Disease Without Crisis

NCT04028700

University of North Carolina, Chapel Hill

20 August 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.